Effect of CD55 single nucleotide polymorphism on the efficacy of pegylated interferon α-2b in chronic hepatitis B patients with HBeAg-positive

Abstract

Abstract: Objective To investigate the effect of CD55 single nucleotide polymorphism (CD55-SNP) on the efficacy of pegylated interferon α-2b (Peg-IFNα-2b) in chronic hepatitis B (CHB) patients with HBeAg-positive. Methods From August 2017 to August 2021, 159 CHB patients with HBeAg-positive were selected. According to the results, CHB patients were divided into response group and non-response group. The clinical data of the two groups were retrospectively analyzed to explore the effect of CD55-SNP on the treatment of patients. Results The GG gene (91.4%) of CD55- rs28371597 was significantly higher than that of CT gene (6.4%) and TT gene (3.2%), and the CFB-rs12614 CC gene (92.4%) was significantly higher than that of CT gene (7.6%) and TT gene (0%) in the response group. Compared with the non-response group (75.0%, 79.1%), the CD55-rs28371597 GG gene (91.4%) and CFB-rs12614 CC gene (92.4%) in the response group increased. According to the analysis of the influencing factors of the treatment effect, the comparison of drinking and CD55-rs28371597 genotype between the two groups was statistically significant. After multivariate calibration, HBV DNA, CFB-rs12614 and STAT4-rs7574865 did not affect the treatment outcome (P>0.05), while CD55-rs28371597 significantly affected the treatment outcome (P<0.05). Conclusion CD55-SNP polymorphism affects the efficacy of Peg-IFNα-2b in CHB patients with HBeAg-positive, and is closely related to virological response. Clinicians can predict the therapeutic effect of Peg-IFNα-2b according to the distribution of CD55-SNP polymorphism and give a reasonable treatment plan.

Key words: CD55 single nucleotide polymorphism, HBeAg, Chronic hepatitis B, Pegylated interferon α-2b, Therapeutic effect

CHEN Ji-liang, ZHOU Wan-yue, XU Ming-chen. Effect of CD55 single nucleotide polymorphism on the efficacy of pegylated interferon α-2b in chronic hepatitis B patients with HBeAg-positive[J]. Chinese Hepatolgy, 2024, 29(11): 1374-1377.

References

[1] Seto WK, Lo YR, Pawlotsky JM, et al. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392(10161):2313-2324.
[2] Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy[J]. Hepatol Int, 2021, 15(5):1031-1048.
[3] Chen XB, Liu FF, Shu FL, et al. Peginterferon alfa-2b combined with tenofovir disoproxil fumarate induced high clinical cure rate in inactive chronic hepatitis B virus carriers[J]. Clin Res Hepatol Gastroenterol, 2021, 45(5):101723.
[4] Li N, Yu K, Dong M, et al. Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy[J]. Emerg Microbes Infect, 2022, 11(1):1876-1889.
[5] Jia N, Gao W, Fan X, et al. Clinical efficacy of PEG-IFNα-2a and PEG-IFNα-2b in the treatment of hepatitis B e antigen-positive hepatitis B and their value in improving inflammatory factors and hemodynamics in patients: A comparative study[J]. Oxid Med Cell Longev, 2022, 2022:3185320.
[6] Lin S, Fu Y, Wu W, et al. The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone[J]. Int J Med Sci, 2020, 17(10):1458-1463.
[7] Zhang C, Yang Z, Wang Z, et al. HBV DNA and HBsAg: Early prediction of response to peginterferon α-2a in HBeAg-negative chronic hepatitis B[J]. Int J Med Sci, 2020, 17(3):383-389.
[8] Chen H, Sun J, Zhou B, et al. Variants in STAT4 associated with cure of chronic HBV infection in HBeAg-positive patients treated with pegylated interferon-alpha[J]. Clin Gastroenterol Hepatol, 2020, 18(1):196-204.e8.
[9] Chen H, Sun J, Zhou B, et al. A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients[J]. Aliment Pharmacol Ther, 2020, 51(4):469-478.
[10] Speed D, Kaphle A, Balding DJ. SNP-based heritability and selection analyses: Improved models and new results[J]. Bioessays, 2022, 44(5):e2100170.
[11] Geller A, Yan J. The role of membrane bound complement regulatory proteins in tumor development and cancer immunotherapy[J]. Front Immunol, 2019, 10:1074.
[12] Togay A, Togay B, Ozbay Gediz D, et al. Levels of lymphocyte-associated regulators of complement system CD55 and CD59 are changed in schizophrenia patients[J]. Int J Psychiatry Clin Pract, 2021, 25(3):277-282.
[13] Khanam A, Chua JV, Kottilil S. Immunopathology of chronic hepatitis B infection: Role of innate and adaptive immune response in disease progression[J]. Int J Mol Sci, 2021, 22(11):5497.
[14] Pouw RB, Ricklin D. Tipping the balance: intricate roles of the complement system in disease and therapy[J]. Semin Immunopathol, 2021, 43(6):757-771.
[15] Shao F, Gao Y, Wang W, et al. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade[J]. Nat Cancer, 2022, 3(10):1192-1210.
[16] Boldt ABW, Oliveira-Toré CF, Kretzschmar GC, et al. Hepatitis B virus infection among leprosy patients: A case for polymorphisms compromising activation of the lectin pathway and complement receptors[J]. Front Immunol, 2021, 11:574457.
[17] Tang Z, Wang L, Huang Z, et al. CD55 is upregulated by cAMP/PKA/AKT and modulates human decidualization via Src and ERK pathway and decidualization-related genes[J]. Mol Reprod Dev, 2022, 89(5-6):256-268.
[18] Zhu C, Song Z, Wang A, et al. Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells[J]. Front Immunol, 2020, 11:1771.
[19] Chen J, Lou S, Chen H, et al. CD55 variant associated with pegylated-interferon α therapy response in HBeAg-positive chronic hepatitis B patients[J]. J Clin Transl Hepatol, 2023, 11(2):295-303.